Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study evaluated the effect of 6 or 12 infusions of different doses of octagam
(intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in
cerebral spinal fluid (CSF) and on the increase of Aβ in blood plasma in patients with mild
to moderate Alzheimer's disease.